It seems that in most cases, big pharma is maintaining a wait-and-see attitude on RNAi-based drugs and will continue to rely on small- molecule approaches to therapeutics. But as patents on blockbuster medicines expire and drug pipelines increasingly run dry, some are looking into whether RNAi can be used for more than target validation. Such is the case with a deal just announced between Sirna Therapeutics and Eli Lilly.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.